Sam Brownback said...

Less than 3 percent of the rare diseases have an FDA-approved treatment.

the G-20 is deeply concerned. They have confronted this debt crisis that is a crisis of confidence as much as anything.

I think we should really look at a key issue, which is the economics of--you know, FDA and NIH can do all the work they ...

The old model of a billion dollars to develop a drug doesn't work in this category.